Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells

BACKGROUND: Anti-CD20 monoclonal antibody treatment has not only increased survival and cure rates in many non-Hodgkin lymphomas, but also has prompted an explosion in the development of novel antibodies and biologically active substances with specific cellular targets in the field of malignancies t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yihu, Yu, Kang, Du, Jimei, Jiang, Lei, Zhang, Shenghui, Han, Yixiang, Yu, Panpan, Tan, Yingxia
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939546/
https://www.ncbi.nlm.nih.gov/pubmed/20815894
http://dx.doi.org/10.1186/1756-9966-29-121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939546/
https://www.ncbi.nlm.nih.gov/pubmed/20815894
http://dx.doi.org/10.1186/1756-9966-29-121

Ejemplares similares